Materiały źródłowe

• #1 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  The goal of treatment in uveitis is to control inflammation in order to prevent vision loss while also limiting the side effects of therapy. Treatments include medical management with ocular or systemic therapy, as well as surgical interventions for diagnostic or therapeutic purposes and for the treatment of complications of uveitis. Treatment strategies depend on the etiology of inflammation and the disease severity and course. If the underlying etiology is infectious, then this must first be treated with appropriate therapy. If the underlying etiology is idiopathic or associated with systemic autoimmune/inflammatory diseases, then a stepladder approach utilizing anti-inflammatory or immunomodulatory therapy may be necessary, often times in coordination with other specialists. […] Corticosteroids are the mainstay of treatment in uveitis and can be administered via multiple routes: topical, local injections (periocular or intraocular), or systemically via oral or intravenous routes.

• #2 Therapeutic Options for Uveitis – Retina Today

  https://retinatoday.com/articles/2017-oct/therapeutic-options-for-uveitis

  Uveitis is an inflammatory condition associated with visual impairment, blindness, and reduced quality of life. The condition often affects patients in their most active and economically productive years. Uveitis has been demonstrated to cause between 5% and 20% of cases of legal blindness in the United States and the European Union, and up to 25% of cases of legal blindness in developing countries. […] Immunomodulatory therapy is essential in controlling chronic inflammation, with decreased risks compared with chronic corticosteroid use. […] Numerous agents are in the pipeline for treatment of uveitis, including long-acting steroid delivery systems, local nonsteroidal agents, systemic therapies, gene therapies, and more. […] Steroid-sparing immunomodulatory therapy, such as antimetabolites (methotrexate and mycophenolate), T-cell inhibitors, alkylating agents, and, more recently, biologics, are commonly used to manage uveitis.

• #3 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  Sometimes, it’s difficult to find a specific cause for uveitis. Even if a specific cause is not identified, uveitis can still be treated successfully. In the majority of cases, identifying a cause for the uveitis does not lead to a cure. It is still necessary to use some form of treatment to control the swelling. […] If uveitis is caused by an underlying condition, treatment may focus on that specific condition. Usually the treatment for uveitis is the same regardless of the cause, as long as the cause is not infectious. The goal of treatment is to reduce the swelling in your eye, as well as in other parts of the body, if present. In some cases, treatment may be necessary for months to years. Several treatment options are available. […] Your doctor may first prescribe eye drops with an anti-inflammatory medication, such as a corticosteroid. Eye drops are usually not enough to treat inflammation beyond the front of the eye, so a corticosteroid injection in or around the eye or corticosteroid tablets (taken by mouth) may be necessary.

• #4 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  The goal of treatment in uveitis is to control inflammation in order to prevent vision loss while also limiting the side effects of therapy. Treatments include medical management with ocular or systemic therapy, as well as surgical interventions for diagnostic or therapeutic purposes and for the treatment of complications of uveitis. Treatment strategies depend on the etiology of inflammation and the disease severity and course. If the underlying etiology is infectious, then this must first be treated with appropriate therapy. If the underlying etiology is idiopathic or associated with systemic autoimmune/inflammatory diseases, then a stepladder approach utilizing anti-inflammatory or immunomodulatory therapy may be necessary, often times in coordination with other specialists. […] Corticosteroids are the mainstay of treatment in uveitis and can be administered via multiple routes: topical, local injections (periocular or intraocular), or systemically via oral or intravenous routes.

• #5 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  Sometimes, it’s difficult to find a specific cause for uveitis. Even if a specific cause is not identified, uveitis can still be treated successfully. In the majority of cases, identifying a cause for the uveitis does not lead to a cure. It is still necessary to use some form of treatment to control the swelling. […] If uveitis is caused by an underlying condition, treatment may focus on that specific condition. Usually the treatment for uveitis is the same regardless of the cause, as long as the cause is not infectious. The goal of treatment is to reduce the swelling in your eye, as well as in other parts of the body, if present. In some cases, treatment may be necessary for months to years. Several treatment options are available. […] Your doctor may first prescribe eye drops with an anti-inflammatory medication, such as a corticosteroid. Eye drops are usually not enough to treat inflammation beyond the front of the eye, so a corticosteroid injection in or around the eye or corticosteroid tablets (taken by mouth) may be necessary.

• #6 Current Diagnosis and Management of Uveitis

  https://www.reviewofophthalmology.com/article/current-diagnosis-and-management-of-uveitis

  Uveitis can be a challenging condition to manage, with a dizzying array of treatment options. These options have varying degrees of efficacy, selection criteria for use, as well as different side effects that also must be taken into account when you’re choosing a treatment path. Here, I’ll review our current options for quelling uveitis and avoiding medication side effects as best we can. […] Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition. Remember, in cases of suspected immune disease that don’t improve or even worsen with steroids or immunosuppression, consider the possibility of infection or malignancy. […] Following are the treatments at your disposal: […] The initial therapy for uveitis is often corticosteroids, which can act quickly to quiet inflammation. Briefly, their mechanism of action relies on their ability to bind to receptors within cells involved in the inflammatory cascade, ultimately leading to the downregulation of pro-inflammatory molecules and cytokines.

• #7 Uveitis I Eye condition information | RNIB

  https://www.rnib.org.uk/your-eyes/eye-conditions-az/uveitis/

  Uveitis affects people in different ways depending on which part of the uvea and eye is affected (front, middle or back). […] Most cases of uveitis get better with treatment. Some types of uveitis are more difficult to treat because they are long-term and have sight-threatening inflammation which can also involve other tissues close by, causing more permanent changes to your sight. […] For most people with acute anterior uveitis a course of eye drops is all the treatment needed to clear up the inflammation. In people with chronic anterior uveitis, they may need long-term medication including immunosuppressants. […] Depending on the level of inflammation in your eye, the dose can range from using the steroid eye drops every hour to using them just once a day. […] Treatment for uveitis can differ from person to person quite considerably and will also consider the cause of your uveitis.

• #8 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  Sometimes, it’s difficult to find a specific cause for uveitis. Even if a specific cause is not identified, uveitis can still be treated successfully. In the majority of cases, identifying a cause for the uveitis does not lead to a cure. It is still necessary to use some form of treatment to control the swelling. […] If uveitis is caused by an underlying condition, treatment may focus on that specific condition. Usually the treatment for uveitis is the same regardless of the cause, as long as the cause is not infectious. The goal of treatment is to reduce the swelling in your eye, as well as in other parts of the body, if present. In some cases, treatment may be necessary for months to years. Several treatment options are available. […] Your doctor may first prescribe eye drops with an anti-inflammatory medication, such as a corticosteroid. Eye drops are usually not enough to treat inflammation beyond the front of the eye, so a corticosteroid injection in or around the eye or corticosteroid tablets (taken by mouth) may be necessary.

• #9 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Systemic steroid therapy may be indicated in cases of vision-threatening uveitis, when there is poor response to topical or local steroid therapy, and in cases of bilateral or systemic involvement. Treatment should consist of high dosage initially and then tapering according to clinical effect. In cases of severe uveitis, intravenous methylprednisolone may be considered (typically 1g/day for three days). […] An important goal in the treatment of uveitis is to minimize the use of corticosteroids and its myriad ocular and systemic adverse effects. The use of immunomodulatory therapy is an essential treatment strategy in the management of noninfectious uveitis (NIU). […] The Multicenter Uveitis Steroid Treatment (MUST) Trial demonstrated that systemic therapy (including corticosteroid-supplemented immunomodulatory therapy and biologic agents) improved visual outcomes, controlled inflammation, and reduced macular edema similarly to local treatment using sustained-release intravitreal fluocinolone acetonide implant in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.

• #10 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Systemic steroid therapy may be indicated in cases of vision-threatening uveitis, when there is poor response to topical or local steroid therapy, and in cases of bilateral or systemic involvement. Treatment should consist of high dosage initially and then tapering according to clinical effect. In cases of severe uveitis, intravenous methylprednisolone may be considered (typically 1g/day for three days). […] An important goal in the treatment of uveitis is to minimize the use of corticosteroids and its myriad ocular and systemic adverse effects. The use of immunomodulatory therapy is an essential treatment strategy in the management of noninfectious uveitis (NIU). […] The Multicenter Uveitis Steroid Treatment (MUST) Trial demonstrated that systemic therapy (including corticosteroid-supplemented immunomodulatory therapy and biologic agents) improved visual outcomes, controlled inflammation, and reduced macular edema similarly to local treatment using sustained-release intravitreal fluocinolone acetonide implant in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.

• #11 Uveitis – Eye Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/uveitis

  Treatment typically includes corticosteroids (as eye drops, taken by mouth, or injected into or around the eye), drops that dilate and relax the pupil in the affected eye, and sometimes medications that suppress the immune system. […] Uveitis treatment must start early to prevent permanent damage. Treatment almost always includes corticosteroids, usually given as eye drops. Corticosteroids can also be taken by mouth or injected into or around the eye. Corticosteroid implants are now available to treat active inflammation of the eye and swelling of the macula (the most critical part of the retina) caused by uveitis. They may, however, accelerate the formation of cataracts and increase the risk of glaucoma. […] Medications to dilate the pupils, such as homatropine or cyclopentolate drops, are also used and can help relieve symptoms.

• #12 Practical Pearls for Managing Anterior Uveitis

  https://www.reviewofoptometry.com/article/practical-pearls-for-managing-anterior-uveitis

  When diagnosing uveitis, let the history and signs guide your treatment plan. […] Regardless, it is important to properly classify the uveitis in order to correctly diagnose and treat the patient, thus eliminating the potential for further complications, including blindness. This article will review typical signs and symptoms of anterior uveitis, as well as discuss essential treatment considerations. […] To properly diagnose and manage uveitis, you must first categorize it. Anterior inflammation confined to the iris and anterior chamber is termed iritis. […] The fundamental purpose in uveitis management hinges on reducing inflammation, thus decreasing morbidity and the likelihood of other, more serious complications, such as vision loss and glaucoma. […] Atropine and other similar cycloplegics/mydriatics play an integral role in all four objectives.

• #13 Uveitis I Eye condition information | RNIB

  https://www.rnib.org.uk/your-eyes/eye-conditions-az/uveitis/

  Apart from certain types of uveitis caused by infection, the key to treating uveitis is to use medications that reduce inflammation and control the immune system. […] Injections are used for intermediate or posterior uveitis to deliver the steroid to the parts of the eye that are inflamed. […] Immunosuppressants can help reduce inflammation by suppressing some of the activity of your immune system. […] If your uveitis is caused by an infection, the infection will need to be treated with antiviral or antibiotic medication, although steroid treatment may be used to help control excessive inflammation. […] Uveitis needs to be treated promptly to try to reduce the risk of further problems that might affect your sight. Good control of inflammation can be achieved in most people, and this reduces the risk of developing complications. […] The treatments that are used for uveitis can have side effects, and may need monitoring, but controlling the uveitis properly with treatments will give a better outcome for your sight than under-treating and allowing the uveitis to continue.

• #14 Uveitis | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/u/uveitis

  How is Uveitis Treated? […] The treatment of uveitis depends on the type seen. Uveitis caused by an infection may require antibiotics or may get better on its own. Uveitis from an unknown cause or that is associated with an autoimmune disease usually requires treatment with medicines. Medicines to treat the inflammation can be given locally in the eye, or by mouth or injection. […] Local treatment with eye drops is usually tried first. Several kinds of eye drops may be used. Steroid eye drops are typically used for treatment. Steroids help to reduce the inflammation. Depending on how much inflammation is present, the steroid eye drops may need to be given several times a day. Drops that dilate the eye are also an important part of treatment. These dilating drops help to prevent adhesions from forming. Adhesions are like bands of scar tissue that can occur as a result of inflammation. If present, the adhesions can prevent the pupil from getting larger or smaller.

• #15 Practical Pearls for Managing Anterior Uveitis

  https://www.reviewofoptometry.com/article/practical-pearls-for-managing-anterior-uveitis

  An IOP rise can occur during the corticosteroid treatment period, but it is not always secondary to the side effects of the corticosteroid itself. […] As such, the term steroid-responder is sometimes wrongly attributed to the healing eye’s normalization of aqueous production before the trabecular meshwork has totally phagocytized the white blood cells and fibrinous protein remnants from the drainage angle. […] It is important to note prostaglandin analogs and miotics should be avoided in uveitis, because they may increase inflammation. […] A common approach may include one drop of homatropine 5% TID for three days, BID for two days and QD for one day; however, an extended period over several weeks may need to be employed for more severe cases. […] The prognosis generally is favorable with appropriate treatment and follow-up regimens; the pillars for proper management remain corticosteroids and cycloplegics.

• #16 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Systemic steroid therapy may be indicated in cases of vision-threatening uveitis, when there is poor response to topical or local steroid therapy, and in cases of bilateral or systemic involvement. Treatment should consist of high dosage initially and then tapering according to clinical effect. In cases of severe uveitis, intravenous methylprednisolone may be considered (typically 1g/day for three days). […] An important goal in the treatment of uveitis is to minimize the use of corticosteroids and its myriad ocular and systemic adverse effects. The use of immunomodulatory therapy is an essential treatment strategy in the management of noninfectious uveitis (NIU). […] The Multicenter Uveitis Steroid Treatment (MUST) Trial demonstrated that systemic therapy (including corticosteroid-supplemented immunomodulatory therapy and biologic agents) improved visual outcomes, controlled inflammation, and reduced macular edema similarly to local treatment using sustained-release intravitreal fluocinolone acetonide implant in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis.

• #17 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  If uveitis is caused by an infection, your doctor may prescribe antibiotics, antiviral medications or other medicines, with or without corticosteroids, to bring the infection under control. […] You may need immunosuppressive drugs if your uveitis affects both eyes, doesn’t respond well to corticosteroids or becomes severe enough to threaten your vision. […] For people with difficult-to-treat posterior uveitis, a device that’s implanted in the eye may be an option. This device slowly releases corticosteroid into the eye for months or years depending on the implant used. […] Uveitis can come back. Make an appointment with your doctor if any of your symptoms reappear or worsen.

• #18 Uveitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK540993/

  Uveitis is a disease process that involves inflammation of the eye. […] This activity reviews the etiology, pathophysiology, evaluation, and management of uveitis and highlights the role of the interprofessional team in evaluating and treating patients with this condition. […] Treatment aims at eliminating inflammation and pain with steroids and topical cycloplegics. Any additional therapies depend on associated processes. For example, anti-viral medications are necessary in herpetic uveitis, while bactrim can be used in toxoplasmic chorioretinitis. Antimetabolite, biologics, and other immunosuppressive medications (e.g., methotrexate, azathioprine, mycophenolate, cyclosporine, adalimumab, and infliximab) are often necessary for chronic, non-infectious cases, especially in cases associated with systemic inflammatory diseases.

• #19 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Uveitis-Treatments.aspx

  Injections can be administered to the side of the eye subconjunctivally or next to the eye periocularly, often with a local anesthetic to numb associated pain. This is usually given as a single dose when symptoms are the most severe, after which other administration methods, such as eye drops, are used. […] Oral tablets or capsules come in a higher dose than other formulations and may be used when as a second-line option, as it is associated with systemic effects of corticosteroids. Where possible, the duration of treatment with oral corticosteroids should be limited to avoid long-term side effects such as weight gain, mood changes and osteoporosis. […] Immunosuppressive medication may be useful to help reduce the inflammation in patients that are unresponsive to other treatments, although must be used with caution. Prior to the administration of immunosuppressive agents, it should be confirmed that the patient does not have a current infection and should be monitored for signs of infection throughout the duration of therapy.

• #20 New Immunosuppressive Therapies in Uveitis Treatment

  https://www.mdpi.com/1422-0067/16/8/18778

  In serious cases of anterior uveitis, unilateral intermediate uveitis, and as an adjuvant in posterior uveitis, periocular corticoids are effective if administered rapidly and with the anti-inflammatory drug administered at a high concentration. […] If certain undesirable side effects appear with corticoid therapy, or if the disease becomes recurrent after leaving corticoids or does not subside, starting therapy with immunosuppressors is indicated in order to permanently withdraw corticoids. […] The most widely used immunosuppressors are T-lymphocyte inhibitors, of which cyclosporine A is stressed because its efficacy compares with corticoids. […] Among antimetabolites, we stress methotrexate (MTX), which has been widely used to treat inflammatory eye diseases ever since Wong and Hersh observed its efficacy in the 1960s.

• #21 A Long-Term Game Plan for Noninfectious Uveitis

  https://www.retina-specialist.com/article/a-longterm-game-plan-for-noninfectious-uveitis

  Treatment requires patience and a nuanced approach. The challenge therefore is not so much diagnosis but executing a proper therapeutic strategy over a time frame measured in years. Noninfectious uveitis will typically respond to local steroids for at least several weeks. At this point, discuss systemic immunomodulatory therapy. Retina specialists have many good options for local therapy, including periocular triamcinolone, intravitreal triamcinolone, the dexamethasone intravitreal implant (Ozurdex, Allergan), and the fluocinolone acetonide 0.59-mg intravitreal implant (Retisert, Bausch + Lomb). Why take on the headache of systemic steroid-sparing therapy? Many patients have bilateral disease, and keeping these eyes out of the operating room is a laudable goal. Systemic therapy may be a better first choice given its efficacy and systemic and ocular safety. Recently reported seven-year extended follow-up showed an average 7.2-letter visual acuity advantage of systemic therapy vs. the fluocinolone implant. A pattern of frequent and significant disease recurrence disrupts a patient’s life and is often an indication for systemic therapy. Classic indicators are anatomic sequelae such as progressive synechiae and iris bombe or angle closure, steroid intraocular pressure (IOP) response, glaucomatous optic atrophy, cataract, vitreous opacity, uveitic macular edema, retinal capillary bed dropout, and macular fibrosis associated with inflammatory choroidal neovascularization. The earlier these severe patients begin systemic therapy, the better they do long term. The following systemic agents are indicated for infectious uveitis: Antimetabolites. The SITE study examined the use of azathioprine, methotrexate and mycophenolate. One lesson from the SITE study is that control rates increase from six to 12 months, so you should emphasize patience and a long-term outlook in patient discussions. Mycophenolate is popular among the antimetabolites because it may have a slightly lower incidence of side effects and thus is often the first choice for initial therapy. Methotrexate is less effective for posterior or panuveitis. Azathioprine is a good intermediate uveitis drug and a decent posterior/panuveitis drug. Cyclosporine is a T-cell inhibitor with a slightly different side effect profile than the antimetabolites. Tacrolimus is a T-cell inhibitor with a side-effect profile and monitoring regimen similar to cyclosporine. Infliximab, given as an intravenous infusion every four to six weeks, had been the prototypical anti-tumor necrosis factor (TNF) agent utilized for uveitis. Adalimumab is the only systemic non-corticosteroid agent FDA-approved for the treatment of noninfectious uveitis. Patients should have negative QuantiFERON testing before they start therapy because the agent may reactivate latent tuberculosis infections. In the last several years, mycophenolate has become increasingly popular as a first drug in all adult age groups. For intermediate uveitis, mycophenolate or azathioprine are good first-line choices. In young patients with significant posterior uveitis or panuveitis, cyclosporine either alone or in combination with mycophenolate or azathioprine is a good first choice. In older patients, the antimetabolite alone can be initiated. In children, methotrexate is often the first drug of choice. A significant body of literature supports the use of systemic immunomodulatory therapy in children with uveitis. Children usually tolerate systemic therapy quite well, so such therapy should be initiated early in the disease course. Local steroid injections have a role for treatment of uveitis in children, but they should be used judiciously and sparingly. Expect inflammatory breakthroughs during systemic therapy, most of which tend to be fairly mild and treatable with topical, injected or oral steroids. The SITE study clearly shows that immunomodulatory therapy takes six to 12 months to take full effect. Many uveitis patients are on prednisone or need prednisone initially, so some suggestions for prednisone use are in order. Chronic oral prednisone requires close attention to sugars, blood pressure and bone density issues. Establish a flare dose. An example: if a patient on mycophenolate and cyclosporine makes it to 3 mg of daily oral prednisone and then has a mild breakthrough, put the prednisone back up to 10 mg, supplement as needed with local steroids, achieve quiescence again and then resume the taper a few weeks or months later. As the SITE study demonstrated, monotherapy works fairly well, but 20 to 40 percent of patients may need combination therapy, either because of progression or recurrences on monotherapy, a desire for steroid-tapering effect or disease severity. If the immunomodulatory regimen has achieved disease quiescence of two years or more, you can consider a taper. The main rule is to proceed slowly.

• #22 New Non-Steroid Treatment for Uveitis | Duke Health

  https://www.dukehealth.org/blog/new-non-steroid-treatment-uveitis

  Shirley Mims thought she would go blind when she was first diagnosed with uveitis. A clinical trial at Duke for a drug now approved by the FDA to treat uveitis helped her see clearly again. […] Uveitis requires comprehensive medical care to prevent irreversible vision loss. […] Duke is one of the few eye centers in North Carolina to offer a comprehensive approach to managing uveitis. […] Dr. Jaffe started Mims on oral steroids, the most common uveitis treatment. […] Humira became the first and only FDA-approved non-steroid treatment for noninfectious uveitis in June 2016. This is an important advance in the treatment of noninfectious uveitis because long-term steroid use often leads to cataracts and glaucoma in uveitis patients. […] The goal of the clinical trial was to determine whether Humira is a safe and effective alternative that could replace or minimize the use of steroids, Dr. Jaffe said. […] Desperate for relief, Mims agreed to try Humira. […] Mims condition improved within three months of starting Humira. […] Three years later, Mims is still on Humira and her condition is considered quiet which means her uveitis is well controlled. […] Dr. Jaffe is a lifesaver, she said.

• #23 The Latest Therapies and Trials in Uveitis – Retina Today

  https://retinatoday.com/articles/2024-july-aug/the-latest-therapies-and-trials-in-uveitis

  Adalimumab extended the time to treatment failure (24 weeks vs 13 weeks for placebo), improved visual acuity, and reduced inflammation, although it led to more adverse events such as injection site and allergic reactions. […] Adalimumab significantly reduced the risk of flare-ups and vision loss following corticosteroid withdrawal, showing a lower treatment failure rate (39% vs 55%) and a significantly longer time to treatment failure (18 months vs 8.3 months) compared with placebo. […] Additional ongoing trials are investigating anti-TNF agents as first-line treatments alone or in combination with other immunosuppressants for various forms of uveitis. […] The results showed that intravitreal injections were more effective than periocular injections in reducing macular thickness and improving visual acuity, although they raised concerns due to potential side effects such as glaucoma and cataract formation.

• #24 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  If uveitis is caused by an infection, your doctor may prescribe antibiotics, antiviral medications or other medicines, with or without corticosteroids, to bring the infection under control. […] You may need immunosuppressive drugs if your uveitis affects both eyes, doesn’t respond well to corticosteroids or becomes severe enough to threaten your vision. […] For people with difficult-to-treat posterior uveitis, a device that’s implanted in the eye may be an option. This device slowly releases corticosteroid into the eye for months or years depending on the implant used. […] Uveitis can come back. Make an appointment with your doctor if any of your symptoms reappear or worsen.

• #25 Uveitis | National Eye Institute

  https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/uveitis

  Treatment: Medicine (usually eye drops, pills, or injections) […] Medicines called steroids can reduce inflammation in your eye. This can ease symptoms and prevent vision loss. Your eye doctor may prescribe steroids in a few different ways: […] Eye drops. Prescription eye drops are the most common treatment. […] Pills. Your eye doctor may also prescribe steroids as a pill. […] Injections. In some cases, your eye doctor might put the steroid in or around your eye with a small needle. […] Implants. If other treatments dont work, your doctor might suggest surgery to put a small device called an implant into your eye. The implant gives you regular small doses of the steroid over time. […] Your treatment plan will depend on several factors like which part of your eye is affected, and other health conditions you have. For example, your doctor may prescribe medicines to help control your immune system. You can work with your doctor to find the right treatments for you.

• #26

  https://link.springer.com/article/10.1007/s10238-022-00954-6

  The specific therapy administered depends on the clinical course of NIU. Short-term treatment is more aggressive for patients with acute uveitis, and a high dose of corticosteroids is needed. In addition, for patients with chronic or recurrent uveitis, a therapeutic plan to control inflammation by using a lower drug dose to reduce adverse events needs to be established. […] Systemic therapy includes both oral and intravenous administration. Before initiating systemic corticosteroids, infectious causes must be ruled out. In addition, it is necessary to assess patients for systemic contraindications for the usage of corticosteroids before initiating therapy. […] Recently, the following intraocular implants have been shown to decrease the frequency of injections and suppress intraocular inflammation: (1) 0.7 mg dexamethasone implants; (2) 0.19 mg fluocinolone acetonide (FA) implants; (3) 0.59 mg FA implants; and (4) 0.18 mg FA implants. These implants minimize the frequency of treatment and prevent the relapse of NIU involving the posterior segment.

• #27 Therapeutic Options for Uveitis – Retina Today

  https://retinatoday.com/articles/2017-oct/therapeutic-options-for-uveitis

  Treatment guidelines discourage use of systemic corticosteroids at doses higher than 10 mg daily due to complications associated with prolonged use. However, local steroids, especially sustained-delivery options, have had increasing importance in the management of uveitis. […] The fluocinolone acetonide intravitreal implant 0.59 mg (Retisert, Bausch + Lomb) was approved by the US Food and Drug Administration (FDA) in 2005. It is surgically implanted to treat noninfectious intermediate uveitis, posterior uveitis, or panuveitis and releases drug for approximately 3 years. […] The MUST trial demonstrated statistically significantly better control of uveitis in the implant group (88% vs. 71%). […] The dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) is a sustained-release, injectable, biodegradable steroid implant approved in the United States and Europe for the treatment of noninfectious uveitis affecting the posterior segment.

• #28 Uveitis: Current and Emerging Diagnostics and Treatments

  https://consultqd.clevelandclinic.org/uveitis-a-review-of-current-and-emerging-diagnostics-and-treatments

  Therapies include steroid implants, immunomodulation and biologics […] There are newer ways of thinking about how we treat uveitis, from local steroid injections to systemic steroid-sparing immunomodulation, as well as local and systemic biologics. […] This treatment may be indicated for: Noninfectious uveitis or uveitic macular edema, Patients with contraindications to systemic therapy, Patients who are intolerant of systemic therapy, Patients with uveitis refractory to systemic therapy. […] The seven-year MUST study showed faster and more complete control of inflammation with the steroid implant versus systemic therapy. […] The dexamethasone intravitreal implant for noninfectious uveitis lasts only about three to four months. […] When treating noninfectious uveitis today, we start with systemic steroid-sparing immunomodulatory therapy (e.g., methotrexate, mycophenolate, azathioprine) as first line.

• #29 Therapeutic Options for Uveitis – Retina Today

  https://retinatoday.com/articles/2017-oct/therapeutic-options-for-uveitis

  Treatment guidelines discourage use of systemic corticosteroids at doses higher than 10 mg daily due to complications associated with prolonged use. However, local steroids, especially sustained-delivery options, have had increasing importance in the management of uveitis. […] The fluocinolone acetonide intravitreal implant 0.59 mg (Retisert, Bausch + Lomb) was approved by the US Food and Drug Administration (FDA) in 2005. It is surgically implanted to treat noninfectious intermediate uveitis, posterior uveitis, or panuveitis and releases drug for approximately 3 years. […] The MUST trial demonstrated statistically significantly better control of uveitis in the implant group (88% vs. 71%). […] The dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) is a sustained-release, injectable, biodegradable steroid implant approved in the United States and Europe for the treatment of noninfectious uveitis affecting the posterior segment.

• #30

  https://link.springer.com/article/10.1007/s10238-022-00954-6

  Ozurdex is a type of intravitreal implant used for NIU patients in whom it can improve visual acuity for up to 6 months and decrease intraocular inflammation. […] Iluvien can release FA for approximately 36 months and play a vital role in decreasing intraocular inflammation. […] Retisert is a novel therapeutic method for chronic NIU, as it allows prolonged local release of steroids into the eye. […] Yutiq can release FA over a period of approximately 3 years, potentially reducing the therapeutic burden in patients with NIU. […] Except for corticosteroid therapy, other therapeutic drugs to treat NIU include traditional immunosuppressants, such as cyclosporine, tacrolimus and antimetabolites. […] The immunosuppressive effects of cyclosporine occur through reversible inhibition of calcineurin and the prevention of inflammatory function of T cells in the peripheral circulation.

• #31 Therapeutic Options for Uveitis – Retina Today

  https://retinatoday.com/articles/2017-oct/therapeutic-options-for-uveitis

  Treatment guidelines discourage use of systemic corticosteroids at doses higher than 10 mg daily due to complications associated with prolonged use. However, local steroids, especially sustained-delivery options, have had increasing importance in the management of uveitis. […] The fluocinolone acetonide intravitreal implant 0.59 mg (Retisert, Bausch + Lomb) was approved by the US Food and Drug Administration (FDA) in 2005. It is surgically implanted to treat noninfectious intermediate uveitis, posterior uveitis, or panuveitis and releases drug for approximately 3 years. […] The MUST trial demonstrated statistically significantly better control of uveitis in the implant group (88% vs. 71%). […] The dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) is a sustained-release, injectable, biodegradable steroid implant approved in the United States and Europe for the treatment of noninfectious uveitis affecting the posterior segment.

• #32 A Long-Term Game Plan for Noninfectious Uveitis

  https://www.retina-specialist.com/article/a-longterm-game-plan-for-noninfectious-uveitis

  Treatment requires patience and a nuanced approach. The challenge therefore is not so much diagnosis but executing a proper therapeutic strategy over a time frame measured in years. Noninfectious uveitis will typically respond to local steroids for at least several weeks. At this point, discuss systemic immunomodulatory therapy. Retina specialists have many good options for local therapy, including periocular triamcinolone, intravitreal triamcinolone, the dexamethasone intravitreal implant (Ozurdex, Allergan), and the fluocinolone acetonide 0.59-mg intravitreal implant (Retisert, Bausch + Lomb). Why take on the headache of systemic steroid-sparing therapy? Many patients have bilateral disease, and keeping these eyes out of the operating room is a laudable goal. Systemic therapy may be a better first choice given its efficacy and systemic and ocular safety. Recently reported seven-year extended follow-up showed an average 7.2-letter visual acuity advantage of systemic therapy vs. the fluocinolone implant. A pattern of frequent and significant disease recurrence disrupts a patient’s life and is often an indication for systemic therapy. Classic indicators are anatomic sequelae such as progressive synechiae and iris bombe or angle closure, steroid intraocular pressure (IOP) response, glaucomatous optic atrophy, cataract, vitreous opacity, uveitic macular edema, retinal capillary bed dropout, and macular fibrosis associated with inflammatory choroidal neovascularization. The earlier these severe patients begin systemic therapy, the better they do long term. The following systemic agents are indicated for infectious uveitis: Antimetabolites. The SITE study examined the use of azathioprine, methotrexate and mycophenolate. One lesson from the SITE study is that control rates increase from six to 12 months, so you should emphasize patience and a long-term outlook in patient discussions. Mycophenolate is popular among the antimetabolites because it may have a slightly lower incidence of side effects and thus is often the first choice for initial therapy. Methotrexate is less effective for posterior or panuveitis. Azathioprine is a good intermediate uveitis drug and a decent posterior/panuveitis drug. Cyclosporine is a T-cell inhibitor with a slightly different side effect profile than the antimetabolites. Tacrolimus is a T-cell inhibitor with a side-effect profile and monitoring regimen similar to cyclosporine. Infliximab, given as an intravenous infusion every four to six weeks, had been the prototypical anti-tumor necrosis factor (TNF) agent utilized for uveitis. Adalimumab is the only systemic non-corticosteroid agent FDA-approved for the treatment of noninfectious uveitis. Patients should have negative QuantiFERON testing before they start therapy because the agent may reactivate latent tuberculosis infections. In the last several years, mycophenolate has become increasingly popular as a first drug in all adult age groups. For intermediate uveitis, mycophenolate or azathioprine are good first-line choices. In young patients with significant posterior uveitis or panuveitis, cyclosporine either alone or in combination with mycophenolate or azathioprine is a good first choice. In older patients, the antimetabolite alone can be initiated. In children, methotrexate is often the first drug of choice. A significant body of literature supports the use of systemic immunomodulatory therapy in children with uveitis. Children usually tolerate systemic therapy quite well, so such therapy should be initiated early in the disease course. Local steroid injections have a role for treatment of uveitis in children, but they should be used judiciously and sparingly. Expect inflammatory breakthroughs during systemic therapy, most of which tend to be fairly mild and treatable with topical, injected or oral steroids. The SITE study clearly shows that immunomodulatory therapy takes six to 12 months to take full effect. Many uveitis patients are on prednisone or need prednisone initially, so some suggestions for prednisone use are in order. Chronic oral prednisone requires close attention to sugars, blood pressure and bone density issues. Establish a flare dose. An example: if a patient on mycophenolate and cyclosporine makes it to 3 mg of daily oral prednisone and then has a mild breakthrough, put the prednisone back up to 10 mg, supplement as needed with local steroids, achieve quiescence again and then resume the taper a few weeks or months later. As the SITE study demonstrated, monotherapy works fairly well, but 20 to 40 percent of patients may need combination therapy, either because of progression or recurrences on monotherapy, a desire for steroid-tapering effect or disease severity. If the immunomodulatory regimen has achieved disease quiescence of two years or more, you can consider a taper. The main rule is to proceed slowly.

• #33 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  If uveitis is caused by an infection, your doctor may prescribe antibiotics, antiviral medications or other medicines, with or without corticosteroids, to bring the infection under control. […] You may need immunosuppressive drugs if your uveitis affects both eyes, doesn’t respond well to corticosteroids or becomes severe enough to threaten your vision. […] For people with difficult-to-treat posterior uveitis, a device that’s implanted in the eye may be an option. This device slowly releases corticosteroid into the eye for months or years depending on the implant used. […] Uveitis can come back. Make an appointment with your doctor if any of your symptoms reappear or worsen.

• #34 Uveitis – Wikipedia

  https://en.wikipedia.org/wiki/Uveitis

  Uveitis is an ophthalmic emergency that requires urgent control of the inflammation to prevent vision loss. Treatment typically involves the use of topical eye drop steroids, intravitreal injection, newer biologics, and treating any underlying disease. […] Uveitis is typically treated with glucocorticoid steroids, either as topical eye drops (prednisolone acetate) or as oral therapy. […] In addition to corticosteroids, topical cycloplegics, such as atropine or homatropine, may be used. […] In severe cases an injection of posterior subtenon triamcinolone acetate may also be given to reduce the swelling of the eye. […] Intravitrial injection of steroid has proven to be a newer useful way to control inflammation for longer without the need for daily eyedrops. […] Non-biologic, steroid sparing therapies for noninfectious uveitis in adults are now more available. […] Antimetabolite medications, such as methotrexate are often used for recalcitrant or more aggressive cases of uveitis. […] In the case of herpetic uveitis, anti-viral medications, such as valaciclovir or aciclovir, may be administered to treat the causative viral infection.

• #35 Uveitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK540993/

  Uveitis is a disease process that involves inflammation of the eye. […] This activity reviews the etiology, pathophysiology, evaluation, and management of uveitis and highlights the role of the interprofessional team in evaluating and treating patients with this condition. […] Treatment aims at eliminating inflammation and pain with steroids and topical cycloplegics. Any additional therapies depend on associated processes. For example, anti-viral medications are necessary in herpetic uveitis, while bactrim can be used in toxoplasmic chorioretinitis. Antimetabolite, biologics, and other immunosuppressive medications (e.g., methotrexate, azathioprine, mycophenolate, cyclosporine, adalimumab, and infliximab) are often necessary for chronic, non-infectious cases, especially in cases associated with systemic inflammatory diseases.

• #36 Uveitis & Iritis » Spokane Eye Clinic

  https://www.spokaneeye.com/specialties/adult-eye-care/uveitis-and-iritis/

  Uveitis Treatment […] Prompt treatment is necessary to minimize any loss of vision. Eye drops, especially steroids and pupil dilators, are medications used to reduce inflammation and pain. For deeper inflammation, oral medication or injections may be necessary. If the uveitis is discovered to be caused by a systemic disease, treatment of that disease may relieve the uveitis. […] Complications such as glaucoma, cataracts, or new blood vessel formation (neovascularization) may also need treatment during the disease. If complications are advanced, surgery may be necessary. […] Uveitis arising in the front or middle part of the eye is commonly more sudden in onset, generally lasting six to eight weeks. In their early stages, it can usually be controlled by the frequent use of steroids and pupil-dilator drops. Often this type of uveitis runs its course before any specific cause is found. Uveitis in the back part of the eye is commonly slower in onset and may last longer. It is also often more difficult to treat.

• #37 Therapeutic Options for Uveitis – Retina Today

  https://retinatoday.com/articles/2017-oct/therapeutic-options-for-uveitis

  EYS606 (Eyevensys) is a nonviral gene therapy that uses a proprietary electrotransfection injection system to deliver plasmids encoding for the production of anti-TNF-alpha into the ciliary muscle of the eye. […] EGP-437 (Eyegate Pharmaceuticals) is a dexamethasone phosphate solution that is delivered to targeted ocular tissues using transscleral iontophoresis. […] NS2 (Aldeyra Therapeutics) is an aldehyde-binding small molecule that traps aldehydes, neutralizing toxic aldehyde species that can lead to inflammation via activation of the nuclear factor kappa B pathway.

• #38 The Latest Therapies and Trials in Uveitis – Retina Today

  https://retinatoday.com/articles/2024-july-aug/the-latest-therapies-and-trials-in-uveitis

  Given the ongoing concerns about the side effects associated with intraocular steroids, alternative approaches have been investigated. […] The PEACHTREE trial evaluated the efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (Xipere, Bausch + Lomb and Clearside Biomedical) in improving vision in patients with noninfectious uveitis complicated by macular edema over 12 weeks, finding that it significantly improved vision with a lower rate of IOP elevation compared with dexamethasone implants in the MERIT trial. […] As uveitis treatment evolves, integrating new findings is crucial.

• #39 Acute Anterior Uveitis – EyeWiki

  https://eyewiki.org/Acute_Anterior_Uveitis

  Acute anterior uveitis is the most common form of uveitis. […] The mainstay of therapy for AAU is topical drops, including corticosteroid drops such as prednisolone acetate 1% and dilating drops such as cyclopentolate. The corticosteroid drop treats the underlying inflammation, while the dilating drop reduces pain and helps to prevent the pupil sticking to the adjacent lens. […] For recurrent or chronic disease and flares that are vision-threatening despite local therapy, systemic immunosuppression therapy may be indicated. […] There is no specific surgical treatment for AAU. Surgery is reserved for dealing with the complications of uveitis. […] Complications include formation of posterior synechiae, band keratopathy, or a rise in intraocular pressure and subsequent glaucoma development. AAU can also cause fluid to accumulate in the macular, the portion of the retina responsible for central vision; this complication is known as cystoid macular edema.

• #40 Uveitis: Symptoms, causes, treatment, and more

  https://www.medicalnewstoday.com/articles/166410

  Which treatment a doctor recommends can vary based on the type of uveitis. […] Some common treatments for anterior uveitis include: eye drops to widen the pupil, drops to reduce pressure on eyes, topical corticosteroids. […] A doctor may use additional methods to treat intermediate, posterior, and anterior uveitis, including: corticosteroids in the form of injections, implants, or oral medication, antivirals, antibiotics, or other medications, nonsteroidal anti-inflammatory drugs to treat pain and swelling, immunosuppressants, corticotropin, biologic agents. […] The treatment they suggest will depend on the underlying cause. […] With early diagnosis and treatment, the outlook for uveitis is often positive. While people can develop complications, there are treatments that can significantly reduce the risk of permanent vision loss. […] A person can reduce their risk of vision loss from uveitis by following all treatment recommendations to reduce inflammation and pressure in the eye.

• #41 Acute Anterior Uveitis – EyeWiki

  https://eyewiki.org/Acute_Anterior_Uveitis

  Acute anterior uveitis is the most common form of uveitis. […] The mainstay of therapy for AAU is topical drops, including corticosteroid drops such as prednisolone acetate 1% and dilating drops such as cyclopentolate. The corticosteroid drop treats the underlying inflammation, while the dilating drop reduces pain and helps to prevent the pupil sticking to the adjacent lens. […] For recurrent or chronic disease and flares that are vision-threatening despite local therapy, systemic immunosuppression therapy may be indicated. […] There is no specific surgical treatment for AAU. Surgery is reserved for dealing with the complications of uveitis. […] Complications include formation of posterior synechiae, band keratopathy, or a rise in intraocular pressure and subsequent glaucoma development. AAU can also cause fluid to accumulate in the macular, the portion of the retina responsible for central vision; this complication is known as cystoid macular edema.

• #42 Anterior uveitis | AOA

  https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/anterior-uveitis

  Prescription eye drops, which dilate the pupils, in combination with anti-inflammatory drugs. Dilating drops will blur vision and increase light sensitivity. However, by relaxing the iris muscles, the eye will be much more comfortable. The treatment takes several days or in some cases several weeks. Never discontinue medications early as this could result in a rapid reoccurrence of the uveitis. […] If the condition does not respond well to prescription drops, injections of steroid medications just under the outer tissue of the eye may be needed. […] Occasionally, oral steroid medications will be used. […] Anterior uveitis usually responds well to treatment; however, the condition tends to recur.

• #43 Uveitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK540993/

  For anterior uveitis, the most common, therapy consists of topical corticosteroids and cycloplegics. Steroids should be tapered according to clinical response to minimize rebound inflammation. […] Intermediate, posterior, and panuveitis treatment is much more complex and should be guided by ophthalmologists, specifically uveitis specialists, when possible.

• #44 Uveitis | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/u/uveitis

  Steroid eye drops work best for anterior uveitis or inflammation in the front of the eye. They do not work as well for the treatment of intermediate or posterior uveitis (inflammation in the middle or back of the eye). It is difficult for the drops to get deeper into the eye. Therefore, a local injection (shot in the eye) of steroids may be used to treat intermediate or posterior uveitis. […] If local treatment is not effective, then your eye doctor may recommend medicines given by mouth, injection or infusion that travel throughout the whole body. This therapy usually consists of stronger anti-inflammatory medications and is usually managed by a rheumatologist instead of the eye doctor. Rheumatologists are doctors that specialize in the treatment of different types of inflammation.

• #45 Uveitis – Symptoms, Causes, Types & Treatment | Dr. Agarwals Eye Hospital

  https://www.dragarwal.com/diseases-conditions/uveitis/

  Taking eye drops containing steroids, such as prednisone, to reduce inflammation. […] Intermediate, posterior, and panuveitis are often treated with injections around the eye, medications given by mouth, or, in some instances, time-release capsules that are surgically implanted inside the eye. Other immunosuppressive agents may be given. A doctor must make sure a patient is not fighting an infection before proceeding with these therapies. […] Some of these medications can have serious side effects, such as glaucoma and cataracts. You may need to visit your doctor for follow-up examinations and blood tests every 1 to 3 months.

• #46 Posterior Uveitis Treatment Orange County | Anterior Uveitis Treatment Long Beach

  https://www.retinasocal.com/posterior-uveitis-vitreo-retinal-surgeon-torrance-huntington-beach-ca.html

  Uveitis is characterized by inflammation of the uvea (a middle layer of the eye which provides blood supply to the retina). Posterior uveitis is one of the four forms of uveitis (anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis) that causes inflammation in the back part of the uvea. […] The treatment of posterior uveitis depends on the cause. Oral steroids are the most common drug of choice for the treatment of posterior uveitis. If the cause is due to infection, then treatment may involve antibiotics, antivirals, along with anti-inflammatory medicines. But, if the cause is autoimmune disorders, then immuno-suppressants and vitamin B12 supplements are recommended.

• #47 Current Diagnosis and Management of Uveitis

  https://www.reviewofophthalmology.com/article/current-diagnosis-and-management-of-uveitis

  In patients with more extensive uveitis, oral prednisone is most commonly used, with the dose ranging between 1 to 1.5 milligrams/kilogram, but, given the side effects, I rarely dose patients above 80 mg even if their weight would dictate a higher amount. […] When starting oral steroids, I keep in mind my endpoints for steroid treatment, so when they’re reached I can begin tapering the medication. […] The rationale for this is twofold: a tapering schedule should be followed after two weeks of high-dose oral steroids instead of abruptly stopping them, as this has been linked to adrenal insufficiency. […] Additionally, I try to get patients off of oral steroids within a reasonable time frame, since they have a multitude of side effects, including decreased bone density; peptic ulcers; Cushing syndrome; blood sugar and blood pressure deregulation; weight gain; immunosuppression; and mood deregulation.

• #48 Current Diagnosis and Management of Uveitis

  https://www.reviewofophthalmology.com/article/current-diagnosis-and-management-of-uveitis

  In patients with more extensive uveitis, oral prednisone is most commonly used, with the dose ranging between 1 to 1.5 milligrams/kilogram, but, given the side effects, I rarely dose patients above 80 mg even if their weight would dictate a higher amount. […] When starting oral steroids, I keep in mind my endpoints for steroid treatment, so when they’re reached I can begin tapering the medication. […] The rationale for this is twofold: a tapering schedule should be followed after two weeks of high-dose oral steroids instead of abruptly stopping them, as this has been linked to adrenal insufficiency. […] Additionally, I try to get patients off of oral steroids within a reasonable time frame, since they have a multitude of side effects, including decreased bone density; peptic ulcers; Cushing syndrome; blood sugar and blood pressure deregulation; weight gain; immunosuppression; and mood deregulation.

• #49 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Surgical interventions may also be necessary in the treatment of complications of uveitis. […] Uncontrolled uveitis is a leading cause of vision loss in the United States and worldwide. These data reinforce the importance of prompt and aggressive treatment of uveitis. The management of the uveitis patient represents a challenge for both the patient and the clinician; therefore, referral to a uveitis specialist should be considered early in the course of the disease. The ultimate goals of treatment of uveitis are to preserve vision, prevent significant vision-related morbidity, and prevent the iatrogenic effects of local and systemic therapies. Finally, treatment of the uveitis patient must always consider the underlying systemic disease. Thus, close collaboration with infectious disease specialists, autoimmune disease specialists, and other medical specialties dedicated to these diseases is of utmost importance.

• #50 Uveitis Treatment | Fort Worth | Ophthalmology Associates

  https://fortworth2020.com/uveitis/

  Uveitis is a broad term that is used to describe inflammation affecting the eyes. […] The treatment of uveitis depends on the cause of the condition. […] In the case of infection, you may be required to take medications directed toward eradicating the infection. […] For noninfectious causes of uveitis, treatment options may include steroid eye drops, local steroid injections, systemic steroids, or systemic immunosuppressive therapy. […] Uveitis specialists often coordinate with other doctors including rheumatologists, neurologists, pulmonologists, cardiologists, and infectious disease doctors. […] If you have uveitis, it is important to follow up with your uveitis specialist regularly, since untreated ocular inflammation can result in permanent damage to the eye and irreversible vision loss.

• #51 Uveitis | Ohio State Medical Center

  https://wexnermedical.osu.edu/eye-care-ophthalmology/conditions-and-services/uveitis

  Uveitis treatments focus on eliminating inflammation, reducing pain and preventing further tissue damage as well as to restore lost vision. […] Your doctor will likely prescribe specific medications for the treatment of uveitis. This medication can be in the form of eye drops, pills, or an injection near or inside your eye. […] When the disease is chronic or reoccurring, your doctor may also recommend immunosuppressive medications taken by mouth. These include methotrexate, azathioprine, cyclosporine and others. […] Here at the Ohio State Wexner Medical Center we utilize and individualized approach to treating uveitis. For those patients with chronic inflammation or rheumatologic conditions we have a multidisciplinary clinic where Ana Suelves Cogollos, MD, PhD, and Beatrice Kenol, MD (an Ohio State Wexner Medical Center rheumatologist) will see patients together to come up with the best treatment plan for your conditions.

• #52 Uveitis

  https://www.nhs.uk/conditions/uveitis/

  If a GP thinks you have uveitis they’ll refer you to an eye specialist (ophthalmologist). You’ll usually be seen within 24 hours, so you can start treatment quickly. […] Depending on what is causing your uveitis and how severe it is, you’ll usually be prescribed a combination of medicines to: get rid of any infection, reduce inflammation, relax the eye and reduce pain. […] If your uveitis is very severe or keeps coming back, you may also be offered other treatments such as: medicines to reduce the activity of your immune system (immunosuppressants) and to reduce inflammation (tumour necrosis factor (TNF) inhibitors), light treatment (laser phototherapy), temporarily freezing part of the eye (cryotherapy), surgery on part of your eye. […] After you’ve started treatment, you’ll be seen again by an ophthalmologist to: see how your treatment is working, check for any side effects of treatment, check for complications of uveitis, such as vision loss.

• #53 Iritis and Uveitis Treatment & Management: Emergency Department Care, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/798323-treatment

  The main goals in the emergency department are to correctly diagnose uveitis, to provide analgesia, and to refer the patient to an ophthalmologist for possible initiation of topical steroids. […] Patients with possible uveitis should be examined by an ophthalmologist within 24 hours. […] Follow-up care with an ophthalmologist within 24 hours is imperative. […] In the acute phase, cases of uveitis are monitored every 1 to 7 days with slit-lamp examination and intraocular pressure measurements. […] The ophthalmologist tapers steroids and cycloplegics. […] Two sustained-release corticosteroid vitreous implants (fluocinolone acetonide [Retisert, Yutiq] and dexamethasone [Ozurdex]) have been approved by the FDA for the treatment of inflammation-induced cases of panuveitis, intermediate uveitis, and posterior uveitis. […] These implants preclude risks associated with systemic steroids and reduce the need for immunosuppressive agents while providing continuous therapy (approximately 30-36 months). […] The installation and monitoring of these treatment modalities should be managed by an ophthalmologist.

• #54 Current approaches to treatment of uveitis with autoimmune disease

  https://europe.ophthalmologytimes.com/view/current-approaches-to-treatment-of-uveitis-with-autoimmune-disease

  Local treatments for NIU are largely corticosteroids, though intraocular injection of agents such as sirolimus and methotrexate have been studied. […] Current approved options for local therapy include topical steroids, shorter-acting intra- and periocular steroids, such as triamcinolone acetonide, and sustained-release intravitreal implants, including Ozurdex (dexamethasone intravitreal implant 0.7 mg, AbbVie) and YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg, EyePoint Pharmaceuticals). […] I usually bring patients on systemic immunosuppressive therapy back for follow-up every 2 to 3 months to examine the eyes for signs of recurrent inflammation and perform blood testing to ensure the efficacy and safety of the therapy. […] We can expect the future of immune-mediated uveitis to feature increasingly targeted and specific therapies, including more biologics and biologic response modifiers, both systemically and locally in the eye.

• #55 Uveitis: Symptoms, Causes, Treatment & Types

  https://my.clevelandclinic.org/health/diseases/14414-uveitis

  Symptom-based treatments usually focus on the following: Pain control. Uveitis can be painful, so pain-reducing treatments are common. These can include medications that prevent spasms of parts of your eye (especially cycloplegics, which temporarily paralyze your iris). Inflammation reduction. Medications like steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) can help reduce pain and inflammation from uveitis. Condition-specific treatments. Examples include antiviral medications, which treat viruses but dont help bacterial, fungal or parasitic infections. […] Uveitis is a common cause of vision loss and legal blindness. In the U.S., 10% of legal blindness cases happen because of, or in connection with, uveitis. Negative outcomes are more likely when there are delays in diagnosis and treatment.

• #56 Uveitis: Symptoms, Causes, Treatment & Types

  https://my.clevelandclinic.org/health/diseases/14414-uveitis

  Symptom-based treatments usually focus on the following: Pain control. Uveitis can be painful, so pain-reducing treatments are common. These can include medications that prevent spasms of parts of your eye (especially cycloplegics, which temporarily paralyze your iris). Inflammation reduction. Medications like steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) can help reduce pain and inflammation from uveitis. Condition-specific treatments. Examples include antiviral medications, which treat viruses but dont help bacterial, fungal or parasitic infections. […] Uveitis is a common cause of vision loss and legal blindness. In the U.S., 10% of legal blindness cases happen because of, or in connection with, uveitis. Negative outcomes are more likely when there are delays in diagnosis and treatment.

• #57 Uveitis: Symptoms, Causes, Treatment & Types

  https://my.clevelandclinic.org/health/diseases/14414-uveitis

  The odds of long-term vision issues are much lower with early diagnosis and treatment. When those happen, youre more likely to recover fully and avoid permanent vision issues. […] If you have uveitis, your eye care specialist will guide you on treatments and tell you what you should do as part of the treatment. Following your eye specialists instructions is important because it can reduce your risk of permanent vision loss. […] Uveitis is a serious eye condition that can cause vision loss. At Cleveland Clinic, our experts will create a treatment plan thats personalized for you.

• #58 Acute Anterior Uveitis – EyeWiki

  https://eyewiki.org/Acute_Anterior_Uveitis

  Acute anterior uveitis is the most common form of uveitis. […] The mainstay of therapy for AAU is topical drops, including corticosteroid drops such as prednisolone acetate 1% and dilating drops such as cyclopentolate. The corticosteroid drop treats the underlying inflammation, while the dilating drop reduces pain and helps to prevent the pupil sticking to the adjacent lens. […] For recurrent or chronic disease and flares that are vision-threatening despite local therapy, systemic immunosuppression therapy may be indicated. […] There is no specific surgical treatment for AAU. Surgery is reserved for dealing with the complications of uveitis. […] Complications include formation of posterior synechiae, band keratopathy, or a rise in intraocular pressure and subsequent glaucoma development. AAU can also cause fluid to accumulate in the macular, the portion of the retina responsible for central vision; this complication is known as cystoid macular edema.

• #59 Uveitis – UF Health Jacksonville

  https://ufhealthjax.org/conditions-and-treatments/uveitis

  Most patients treated for acute uveitis do not lose their vision. The main causes of visual loss in patients with chronic uveitis are cataracts, glaucoma or damage to the back of the eye from pressure inside the eye and macular edema of the retina. The two most important factors in preventing permanent loss of vision are to control the inflammation and ensure that the intraocular pressure is not elevated.

• #60 Uveitis – UF Health Jacksonville

  https://ufhealthjax.org/conditions-and-treatments/uveitis

  Most patients treated for acute uveitis do not lose their vision. The main causes of visual loss in patients with chronic uveitis are cataracts, glaucoma or damage to the back of the eye from pressure inside the eye and macular edema of the retina. The two most important factors in preventing permanent loss of vision are to control the inflammation and ensure that the intraocular pressure is not elevated.

• #61 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Surgical interventions may also be necessary in the treatment of complications of uveitis. […] Uncontrolled uveitis is a leading cause of vision loss in the United States and worldwide. These data reinforce the importance of prompt and aggressive treatment of uveitis. The management of the uveitis patient represents a challenge for both the patient and the clinician; therefore, referral to a uveitis specialist should be considered early in the course of the disease. The ultimate goals of treatment of uveitis are to preserve vision, prevent significant vision-related morbidity, and prevent the iatrogenic effects of local and systemic therapies. Finally, treatment of the uveitis patient must always consider the underlying systemic disease. Thus, close collaboration with infectious disease specialists, autoimmune disease specialists, and other medical specialties dedicated to these diseases is of utmost importance.

• #62 Uveitis – Diagnosis and Treatment at the UPMC Vision Institute

  https://www.upmc.com/services/eye/conditions/uveitis

  Uveitis needs to be promptly treated with topical and/or oral steroids to avoid vision-threatening complications. […] The easiest and best way to treat uveitis is with topical steroid eye drops. These drops typically are used for several weeks. Sometimes oral steroids may be needed to treat uveitis. It is important that patients taking steroids visit their doctor frequently because steroids can cause glaucoma and cataracts. […] Some patients also may receive a drop that will dilate their pupils and keep the iris in one place, which is more comfortable. These drops, however, may temporarily increase focusing problems and cause light sensitivity.

• #63 Acute Anterior Uveitis – EyeWiki

  https://eyewiki.org/Acute_Anterior_Uveitis

  Some forms of AAU have a tendency to recur. Prompt initiation of treatment at the time of recurrence may shorten the duration of the attack or improve the prognosis, but treatment should always be guided by a physician who has confirmed the patient’s suspected diagnosis at the earliest possible time.

• #64 Uveitis – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/uveitis/diagnosis-treatment/drc-20378739

  If uveitis is caused by an infection, your doctor may prescribe antibiotics, antiviral medications or other medicines, with or without corticosteroids, to bring the infection under control. […] You may need immunosuppressive drugs if your uveitis affects both eyes, doesn’t respond well to corticosteroids or becomes severe enough to threaten your vision. […] For people with difficult-to-treat posterior uveitis, a device that’s implanted in the eye may be an option. This device slowly releases corticosteroid into the eye for months or years depending on the implant used. […] Uveitis can come back. Make an appointment with your doctor if any of your symptoms reappear or worsen.

• #65 Uveitis – UF Health Jacksonville

  https://ufhealthjax.org/conditions-and-treatments/uveitis

  Uveitis in the front and middle part of the eye usually can be controlled by the frequent use of drops. Uveitis in the back part of the eye often is more difficult to treat. […] If your uveitis responds poorly to corticosteroids or becomes severe enough to threaten your vision, you may need a different kind of medication, such as an immunosuppressive or cytotoxic agent. Vitrectomy surgery to remove the jelly-like material in your eye (vitreous) may sometimes be necessary for diagnosis and treatment of uveitis. […] Uveitis can recur, so it’s important to see your doctor if your symptoms reappear after successful treatment. […] No. Treatment only suppresses the harmful inflammation until the disease process is stopped by your body’s own healing process. The treatment needs to be continued as long as the inflammation is active. In any patient, it is not possible to know how long the disease will last.

• #66 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Surgical interventions may also be necessary in the treatment of complications of uveitis. […] Uncontrolled uveitis is a leading cause of vision loss in the United States and worldwide. These data reinforce the importance of prompt and aggressive treatment of uveitis. The management of the uveitis patient represents a challenge for both the patient and the clinician; therefore, referral to a uveitis specialist should be considered early in the course of the disease. The ultimate goals of treatment of uveitis are to preserve vision, prevent significant vision-related morbidity, and prevent the iatrogenic effects of local and systemic therapies. Finally, treatment of the uveitis patient must always consider the underlying systemic disease. Thus, close collaboration with infectious disease specialists, autoimmune disease specialists, and other medical specialties dedicated to these diseases is of utmost importance.

• #67 Treatment of Uveitis – EyeWiki

  https://eyewiki.org/Treatment_of_Uveitis

  Surgical interventions may also be necessary in the treatment of complications of uveitis. […] Uncontrolled uveitis is a leading cause of vision loss in the United States and worldwide. These data reinforce the importance of prompt and aggressive treatment of uveitis. The management of the uveitis patient represents a challenge for both the patient and the clinician; therefore, referral to a uveitis specialist should be considered early in the course of the disease. The ultimate goals of treatment of uveitis are to preserve vision, prevent significant vision-related morbidity, and prevent the iatrogenic effects of local and systemic therapies. Finally, treatment of the uveitis patient must always consider the underlying systemic disease. Thus, close collaboration with infectious disease specialists, autoimmune disease specialists, and other medical specialties dedicated to these diseases is of utmost importance.

• #68 Current approaches to treatment of uveitis with autoimmune disease

  https://europe.ophthalmologytimes.com/view/current-approaches-to-treatment-of-uveitis-with-autoimmune-disease

  Local treatments for NIU are largely corticosteroids, though intraocular injection of agents such as sirolimus and methotrexate have been studied. […] Current approved options for local therapy include topical steroids, shorter-acting intra- and periocular steroids, such as triamcinolone acetonide, and sustained-release intravitreal implants, including Ozurdex (dexamethasone intravitreal implant 0.7 mg, AbbVie) and YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg, EyePoint Pharmaceuticals). […] I usually bring patients on systemic immunosuppressive therapy back for follow-up every 2 to 3 months to examine the eyes for signs of recurrent inflammation and perform blood testing to ensure the efficacy and safety of the therapy. […] We can expect the future of immune-mediated uveitis to feature increasingly targeted and specific therapies, including more biologics and biologic response modifiers, both systemically and locally in the eye.

• #69 Emerging Therapies and Advancements in Uveitis Treatment

  https://www.delveinsight.com/blog/uveitis-treatment

  There is a requirement for enhanced initial treatment of inflammation, improved maintenance of persistent chronic inflammation, and better handling of disease complications like macular edema. […] The treatment of uveitis is evolving with newer drugs and innovative advances in ocular drug delivery. This is due to a better understanding of the pathophysiology of the disease and the barriers to drug delivery. Several emerging therapies for uveitis treatment show promise in improving outcomes for patients. […] Emerging therapies for uveitis treatment are filled with promise in improving treatment outcomes and reducing side effects associated with current therapies. While further research is needed to establish their safety and efficacy, these therapies offer newer possibilities for alternatives or adjuncts to traditional therapies for patients with uveitis.

Zobacz więcej